BRPI0413843A - enhancement of activation of high molecular weight prodrugs - Google Patents

enhancement of activation of high molecular weight prodrugs

Info

Publication number
BRPI0413843A
BRPI0413843A BRPI0413843-0A BRPI0413843A BRPI0413843A BR PI0413843 A BRPI0413843 A BR PI0413843A BR PI0413843 A BRPI0413843 A BR PI0413843A BR PI0413843 A BRPI0413843 A BR PI0413843A
Authority
BR
Brazil
Prior art keywords
molecular weight
high molecular
activation
enhancement
prodrugs
Prior art date
Application number
BRPI0413843-0A
Other languages
Portuguese (pt)
Inventor
Andre Trouet
Vincent Dubois
Original Assignee
Diatos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatos filed Critical Diatos
Publication of BRPI0413843A publication Critical patent/BRPI0413843A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"POTENCIALIZAçãO DA ATIVAçãO DE PRó-MEDICAMENTOS DE ELEVADO PESO MOLECULAR". A presente invenção se refere a uma forma modificada de um pró-medicamento. Uma forma típica de pró-medicamento segundo a invenção compreende um grupo volumoso, um espaçador, uma estrutura clivável no aparelho circulatório e um agente terapêutico ou um marcador; o dito espaçador permite ou facilita a clivagem da estrutura clivável."POTENTIALIZATION OF HIGH MOLECULAR WEIGHT PRODUCT ACTIVATION". The present invention relates to a modified form of a prodrug. A typical form of prodrug according to the invention comprises a bulky group, a spacer, a circulatory cleavable structure and a therapeutic agent or marker; said spacer allows or facilitates cleavage of the cleavable structure.

BRPI0413843-0A 2003-08-22 2004-08-19 enhancement of activation of high molecular weight prodrugs BRPI0413843A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0310114A FR2858936A1 (en) 2003-08-22 2003-08-22 New active compound precursor, useful as therapeutic or diagnostic agent or tracer, includes cleavable component that increases half-life in the circulation, attached through hydrophilic spacer
PCT/FR2004/002162 WO2005021043A2 (en) 2003-08-22 2004-08-19 High-molecular-mass prodrugs

Publications (1)

Publication Number Publication Date
BRPI0413843A true BRPI0413843A (en) 2006-10-24

Family

ID=34112859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413843-0A BRPI0413843A (en) 2003-08-22 2004-08-19 enhancement of activation of high molecular weight prodrugs

Country Status (8)

Country Link
EP (1) EP1701743A2 (en)
JP (1) JP2007503382A (en)
AU (1) AU2004268405A1 (en)
BR (1) BRPI0413843A (en)
CA (1) CA2536442A1 (en)
FR (1) FR2858936A1 (en)
IL (1) IL173760A0 (en)
WO (1) WO2005021043A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010764A (en) * 2004-03-23 2006-12-15 Amgen Inc Chemically modified protein compositions and methods.
US8138308B2 (en) * 2005-12-27 2012-03-20 Mcmaster University Modified peptide substrate
CA2645347A1 (en) * 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
BRPI0920655A2 (en) * 2008-10-07 2019-07-09 Rexahn Pharmaceuticals Inc conjugates and hpma-docetaxel or gemcitabine and their uses
KR20100083632A (en) * 2009-01-14 2010-07-22 울산대학교 산학협력단 Anticancer prodrug sensitive to target protease
AU2010306917B2 (en) 2009-10-13 2014-11-27 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535665T2 (en) * 1994-08-19 2009-04-02 La Region Wallonne CONJUGATES CONTAIN AN ANTITUMORAL AGENT AND ITS USE
WO2001091798A2 (en) * 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
WO2001095945A2 (en) * 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds cleavable by thimet oligopeptidase

Also Published As

Publication number Publication date
AU2004268405A1 (en) 2005-03-10
IL173760A0 (en) 2006-07-05
EP1701743A2 (en) 2006-09-20
WO2005021043A3 (en) 2006-06-15
CA2536442A1 (en) 2005-03-10
WO2005021043A2 (en) 2005-03-10
FR2858936A1 (en) 2005-02-25
JP2007503382A (en) 2007-02-22

Similar Documents

Publication Publication Date Title
CY1111433T1 (en) PHARMACEUTICAL PREPARED FORM
UY29112A1 (en) DERIVATIVES OF CONDENSED PIRAZOL, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION
DOP2007000053A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE
GT200500137A (en) USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS.
DE60315145D1 (en) HYDROPHILIC Y-BRANCH POLYMER DERIVATIVE AND METHOD OF MANUFACTURING THEREOF; ABOVE CONNECTED MEDICAL COMPOSITE
BRPI0508557A (en) pharmaceutical composition comprising pimobendan
UY30578A1 (en) NEW DERIVATIVES OF 2,4 ?? - AND 3, 4 ?? - BIPIRIDINA SUBSTITUTED, PROCEDURES FOR THEIR PREPARATION, MEDICINES CONTAINING THEM AND APPLICATIONS
UY30426A1 (en) SUBSTITUTED DERIVATIVES OF 3- (4-METOXI-PHENYL) -3H-ISOINDOL-1-ILLUMIN TRIFLUOROACETATE, ITS SALTS OR SOLVATOS PHARMACEUTICALLY ACCEPTABLE, PHARMACEUTICAL FORMULATIONS AND APPLICATIONS.
DE60144392D1 (en) ANTIVIRAL MEDIUM
CY1111709T1 (en) PHOSPHONIC NUCLEOSIDE CONNECTION PRODUCTS AS ANTI-HIV AGENTS
DE60325379D1 (en) Composition containing 6-Ä3- (1-adamantyl) -4-methoxyphenyl-2-naphthanoic acid for the treatment of dermatological diseases
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
BRPI0612309B8 (en) antiviral compounds and pharmaceutical compositions
BRPI0509863A (en) drug release to the eye fundus
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
HK1116073A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
BRPI0512352A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
IS6997A (en) Pharmacologically active uridine esters
HN2001000037A (en) DERIVATIVES OF ETERES DE PIRAZOL AS ANTI-INFLAMMATORY / ANALGESIC AGENTS
BRPI0414565A (en) pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
UY30778A1 (en) COMPOUNDS OF 5,6-DIHIDRO-1H-PIRIDIN-2-ONA
BRPI0506493A (en) therapeutic combinations
MA32841B1 (en) Compounds of cyclondica dipseibeptides and their use as drugs
WO2010066931A4 (en) Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/64 (2017.01), A61K 47/60 (2017.01), A61K 4